This randomized noninferiority trial sought to compare the efficacy and safety of a new epoetin formulation developed by Bio-Manguinhos , a biologics manufacturer affiliated with the Brazilian government , with those of a commercially available product currently used in Brazil ( a biosimilar epoetin formulation ) .